SGRQ total score averaged over 24 wk: cilomilast improved ~3.6 points vs placebo worsened ~0.5 points (p < 0.001) pts. exacerbation-free at 24 wk: cilomilast 74% vs placebo 62% (p = 0.008 ...

Setrusumab receives Breakthrough Therapy designation from the FDACash of $80.5 million as of September 30, 2024, expected to fund operations into ...

SGRQ = St. George Respiratory Questionnaire; SF-36 = Medical Outcomes Study 36-item short form; DLCO = diffusing capacity of the lung for carbon monoxide; NS = not significant; IVC = inspiratory ...

The inter-rater/test–retest reliability and construct validity of a palliative care needs assessment tool in interstitial lung disease (NAT:PD-ILD) were tested ...

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo ...